Ependymoblastoma (ETMR): Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Ependymoblastoma, now reclassified under WHO 2021 as CNS embryonal tumor with multilayered rosettes (ETMR), is an extremely rare and highly aggressive primary brain tumor that arises almost exclusively in children under 4 years of age, with the majority diagnosed before 2 years of life. The defining molecular hallmark is amplification of the C19MC microRNA cluster on chromosome 19q13.42, detected by FISH, which distinguishes ETMR from all other pediatric CNS tumors. Historically confused with ependymoma due to its rosette architecture, ETMR is now recognized as a biologically distinct entity with an extremely poor prognosis, with median overall survival of less than 12 months despite aggressive multimodal therapy. The WHO 2021 integrated category encompasses entities previously named ependymoblastoma, embryonal tumor with abundant neuropil and true rosettes (ETANTR), and medulloepithelioma. Due to extreme rarity (estimated incidence under 1 per million children per year), international cooperative research through consortia such as the German HIT-SKK group is critical.

ETMR is defined by acquired somatic amplification of the C19MC microRNA cluster at chromosome 19q13.42, occurring as a somatic, non-inherited event in virtually all cases. The C19MC cluster encodes over 50 microRNAs that suppress differentiation and promote stem cell self-renewal, contributing to the tumor's primitive and aggressive biology. No confirmed germline predisposition syndrome has been identified for ETMR. A small minority of ETMR cases harbor DICER1 mutations, typically in patients with pleuropulmonary blastoma family tumor and dysplasia syndrome (DICER1 syndrome), which also predisposes to PPB, thyroid tumors, and ovarian Sertoli-Leydig cell tumors. The tumor arises from primitive neuroepithelial stem cells during early brain development. There are no known environmental or preventable risk factors for this sporadic tumor.

ETMR presents with rapidly progressive neurological deterioration reflecting the aggressive biology of the tumor. In infants under 12 months, symptoms include macrocephaly from hydrocephalus, a tense or bulging fontanelle, disproportionate irritability, poor feeding, and developmental stagnation or regression. In toddlers and young children (12 months to 4 years), presenting features include headache, recurrent vomiting (particularly in the morning), gait instability and falls from cerebellar dysfunction, and new-onset seizures when the tumor involves the cerebral cortex. Supratentorial tumors may cause focal neurological deficits including hemiparesis, speech difficulties, and visual disturbances. Leptomeningeal dissemination at diagnosis — present in approximately 30–50% of patients — may cause back pain, leg weakness, or bowel and bladder dysfunction in older children.

MRI of the entire brain and spinal cord with gadolinium contrast is the essential imaging study, demonstrating a large, heterogeneous, often supratentorial mass with peripheral enhancement, areas of hemorrhage and necrosis, and leptomeningeal dissemination in a substantial proportion of cases. Histopathology reveals the characteristic multilayered (ependymoblastic) rosettes embedded within a neuropil-rich background. Immunohistochemistry is positive for LIN28A in virtually all ETMR cases — a highly specific marker. FISH for C19MC amplification at 19q13.42 is required for definitive molecular diagnosis per WHO 2021 criteria. DNA methylation array profiling (Heidelberg Brain Tumor Classifier) provides additional confirmation of the ETMR methylation class. CSF cytology obtained postoperatively assesses leptomeningeal spread for staging.

Maximal safe surgical resection is the initial treatment goal, though the often large size, eloquent brain location, and involvement of multiple lobes may limit the extent achievable. Post-surgical treatment in children under 3–4 years (the predominant age group) involves high-dose multi-agent chemotherapy designed to delay or replace craniospinal irradiation. Infant-type chemotherapy protocols (such as HIT-SKK or Baby Brain regimens) use induction chemotherapy with carboplatin, vincristine, cyclophosphamide, and etoposide, followed in responding patients by consolidation high-dose chemotherapy with thiotepa and autologous stem cell rescue. Intraventricular chemotherapy (methotrexate, etoposide) administered via Ommaya reservoir targets leptomeningeal disease. Craniospinal irradiation is deferred or avoided in children under 3 years due to severe and irreversible neurotoxic effects on the developing brain, including profound neurocognitive impairment, endocrinopathies, and growth failure. All patients should be enrolled in clinical trials at specialized pediatric neuro-oncology centers.

The prognosis of ETMR is extremely poor, with median overall survival of less than 12 months regardless of treatment. Long-term survivors are rare, reported in isolated case series at specialized centers, typically in patients achieving complete surgical resection and responding to high-dose chemotherapy. The combination of very young patient age precluding standard craniospinal radiation, extremely aggressive tumor biology driven by C19MC amplification, frequent leptomeningeal dissemination at diagnosis, and absence of any established effective systemic therapy contributes to near-universal treatment failure. International cooperative clinical trials through SIOPE (Society for Paediatric Oncology and Haematology in Europe) and CERN (Collaborative Ependymoma Research Network) are essential to make progress in this disease.

No preventive strategies exist for sporadic ETMR, as no environmental risk factors have been identified and the defining C19MC amplification occurs as a somatic event. However, patients with confirmed DICER1 syndrome (germline DICER1 mutations) — which has a small but established association with ETMR — should be referred to a clinical genetics service for family counseling and surveillance. Family members of DICER1 syndrome patients should be offered cascade genetic testing. Patients with DICER1 syndrome require surveillance with annual chest X-ray (for pleuropulmonary blastoma), thyroid ultrasound, and brain imaging protocols per established DICER1 surveillance guidelines. Clinical trial enrollment at diagnosis is strongly encouraged given the desperate need for effective therapies. Families of children with ETMR benefit from connection to patient advocacy organizations and rare pediatric brain tumor support networks.

Any infant or young child with rapidly worsening, unexplained irritability combined with a bulging fontanelle, increasing head circumference, vomiting, or developmental regression requires immediate pediatric evaluation — these may indicate raised intracranial pressure from a brain tumor. A child aged 1–4 years with persistent or progressive early-morning headaches, recurrent projectile vomiting, gait instability or frequent falls, or sudden-onset seizures needs urgent brain imaging (MRI). These symptoms evolve quickly in ETMR and require emergency evaluation without delay. In children where a supratentorial CNS mass is found on imaging, urgent referral to a pediatric neurosurgery center with neuro-oncology expertise is essential, as diagnosis and treatment at specialized centers provide the best possible outcome in this rare and aggressive tumor.